NCT01201694View on ClinicalTrials.gov

Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L)

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Advanced Cancers
Interventions
DRUG

Surface-Controlled Water Soluble Curcumin

Starting dose 100 mg by mouth two times a day of a 28 day cycle.

DRUG

Surface-Controlled Water Soluble Curcumin MTD

Dose will be maximum tolerated dose (MTD) from Arm 1.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Gateway for Cancer Research

OTHER

collaborator

Theravalues, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT01201694 - Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L) | Biotech Hunter | Biotech Hunter